UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 133

Sortiert nach

Safety Profile of Ixazomib in Patients with Relapsed/Refractory Multiple Myeloma in Japan: An All-case Post-marketing Surveillance

Internal Medicine, 2022/05/01, Vol.61(9), pp.1337-1343

2022

Link zum Volltext

Verfügbarkeit prüfen

A phase 2, open-label, multicenter study of ixazomib plus lenalidomide and dexamethasone in adult Japanese patients with relapsed and/or refractory multiple myeloma

International journal of clinical oncology, 2022-01, Vol.27 (1), p.224-233

2022

Link zum Volltext

Verfügbarkeit prüfen

Multiple Myeloma : Recent Progress in Diagnosis and Treatment

Journal of Clinical and Experimental Hematopathology, 2012, Vol.52(3), pp.149-159

Chou, Takaaki

2012

Link zum Volltext

Verfügbarkeit prüfen

Autologous hematopoietic cell transplantation for acute myeloid leukemia in adults: 25 years of experience in Japan

International journal of hematology, 2020-01, Vol.111 (1), p.93-102

2020

Link zum Volltext

Verfügbarkeit prüfen

Weekly carfilzomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma: A phase 1 and PK/PD trial

Cancer science, 2018-10, Vol.109 (10), p.3245-3252

2018

Link zum Volltext

Verfügbarkeit prüfen

High-dose therapy and autologous stem cell transplantation for relapsed or high-risk diffuse large B-cell lymphoma: a nationwide survey

International journal of hematology, 2020-02, Vol.111 (2), p.256-266

2020

Link zum Volltext

Verfügbarkeit prüfen

Phase I, multicenter, dose‐escalation study of avadomide in adult Japanese patients with advanced malignancies

Cancer science, 2021-01, Vol.112 (1), p.331-338

2021

Link zum Volltext

Verfügbarkeit prüfen

A Phase I/II Study for Dose-finding, and to Investigate the Safety, Pharmacokinetics and Preliminary Efficacy of NK012, an SN-38-Incorporating Macromolecular Polymeric Micelle, in Patients with Multiple Myeloma

Internal Medicine, 2018/04/01, Vol.57(7), pp.939-946

2018

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of weekly carfilzomib (70 mg/m2), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies

Leukemia & lymphoma, 2021-01, Vol.62 (2), p.358-367

2021

Link zum Volltext

Verfügbarkeit prüfen

Clinical profiles of multiple myeloma in Asia—An Asian Myeloma Network study

American journal of hematology, 2014-07, Vol.89 (7), p.751-756

2014

Link zum Volltext

Verfügbarkeit prüfen

Phase 1 study of ixazomib alone or combined with lenalidomide-dexamethasone in Japanese patients with relapsed/refractory multiple myeloma

International journal of hematology, 2017-04, Vol.105 (4), p.445-452

2017

Link zum Volltext

Verfügbarkeit prüfen

Carfilzomib monotherapy in Japanese patients with relapsed or refractory multiple myeloma: A phase 1/2 study

Cancer science, 2019-09, Vol.110 (9), p.2924-2932

2019

Link zum Volltext

Verfügbarkeit prüfen

Carfilzomib, lenalidomide and dexamethasone in patients with heavily pretreated multiple myeloma: A phase 1 study in Japan

Cancer science, 2017-03, Vol.108 (3), p.461-468

2017

Link zum Volltext

Verfügbarkeit prüfen

A phase 3b, multicenter, open-label extension study of the long-term safety of anagrelide in Japanese adults with essential thrombocythemia

International journal of hematology, 2018-11, Vol.108 (5), p.491-498

2018

Link zum Volltext

Verfügbarkeit prüfen

Retraction Note to: High-dose therapy and autologous stem cell transplantation for relapsed or high-risk diffuse large B-cell lymphoma: a nationwide survey

International journal of hematology, 2020-12, Vol.112 (6), p.907-907

2020

Link zum Volltext

Verfügbarkeit prüfen

Therapeutic strategy for multiple myeloma -recent progress

Annals of oncology, 2016-11, Vol.27, p.vii72

Chou, Takaaki

2016

Link zum Volltext

Verfügbarkeit prüfen

Final results of a phase I study of carfilzomib, lenalidomide, and dexamethasone for heavily pretreated multiple myeloma

International journal of hematology, 2020, Vol.111 (1), p.57-64

2020

Link zum Volltext

Verfügbarkeit prüfen

Future projection of cancer patients with cardiovascular disease in Japan by the year 2039: a pilot study

International journal of clinical oncology, 2019-08, Vol.24 (8), p.983-994

2019

Link zum Volltext

Verfügbarkeit prüfen

RETRACTED ARTICLE: High-dose therapy and autologous stem cell transplantation for relapsed or high-risk diffuse large B-cell lymphoma: a nationwide survey

International journal of hematology, 2020-02, Vol.111 (2), p.256-266

2020

Link zum Volltext

Verfügbarkeit prüfen

Management of multiple myeloma in Asia: resource-stratified guidelines

The lancet oncology, 2013-11, Vol.14 (12), p.e571-e581

2013

Link zum Volltext

Verfügbarkeit prüfen

Pomalidomide alone or in combination with dexamethasone in Japanese patients with refractory or relapsed and refractory multiple myeloma

Cancer science, 2015-11, Vol.106 (11), p.1561-1567

2015

Link zum Volltext

Verfügbarkeit prüfen

Survival of Multiple Myeloma Patients Aged 65-70 Years in the Era of Novel Agents and Autologous Stem Cell Transplantation

Acta haematologica, 2014-01, Vol.132 (2), p.211-219

2014

Link zum Volltext

Verfügbarkeit prüfen

Elotuzumab with lenalidomide and dexamethasone for Japanese patients with relapsed/refractory multiple myeloma: phase 1 study

International journal of hematology, 2017-03, Vol.105 (3), p.326-334

2017

Link zum Volltext

Verfügbarkeit prüfen

Risk factors and timing of autologous stem cell transplantation for patients with peripheral T-cell lymphoma

International journal of hematology, 2019-02, Vol.109 (2), p.175-186

2019

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 133

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(117)
Mit Volltextzugriff
(118)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(82)
Life Sciences & Biomedicine
(74)
Humans
(67)
Hematology
(50)
Male
(49)
Female
(47)
Oncology
(46)
Middle Aged
(44)
Adult
(37)
Aged
(37)
Multiple Myeloma
(35)
Medicine
(26)
Medicine & Public Health
(26)
Multiple Myeloma - Drug Therapy
(23)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(21)
Original Article
(20)
Japan
(19)
Treatment Outcome
(19)
Biological And Medical Sciences
(18)
Medical Sciences
(18)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Safety Profile of Ixazomib in Patients with Relapsed/Refractory Multiple Myeloma in Japan: An All-case Post-marketing Surveillance

A phase 2, open-label, multicenter study of ixazomib plus lenalidomide and dexamethasone in adult Japanese patients with relapsed and/or refractory multiple myeloma

Multiple Myeloma : Recent Progress in Diagnosis and Treatment

Autologous hematopoietic cell transplantation for acute myeloid leukemia in adults: 25 years of experience in Japan

Weekly carfilzomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma: A phase 1 and PK/PD trial

High-dose therapy and autologous stem cell transplantation for relapsed or high-risk diffuse large B-cell lymphoma: a nationwide survey

Phase I, multicenter, dose‐escalation study of avadomide in adult Japanese patients with advanced malignancies

A Phase I/II Study for Dose-finding, and to Investigate the Safety, Pharmacokinetics and Preliminary Efficacy of NK012, an SN-38-Incorporating Macromolecular Polymeric Micelle, in Patients with Multiple Myeloma

Efficacy and safety of weekly carfilzomib (70 mg/m2), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies

Clinical profiles of multiple myeloma in Asia—An Asian Myeloma Network study

Phase 1 study of ixazomib alone or combined with lenalidomide-dexamethasone in Japanese patients with relapsed/refractory multiple myeloma

Carfilzomib monotherapy in Japanese patients with relapsed or refractory multiple myeloma: A phase 1/2 study

Carfilzomib, lenalidomide and dexamethasone in patients with heavily pretreated multiple myeloma: A phase 1 study in Japan

A phase 3b, multicenter, open-label extension study of the long-term safety of anagrelide in Japanese adults with essential thrombocythemia

Retraction Note to: High-dose therapy and autologous stem cell transplantation for relapsed or high-risk diffuse large B-cell lymphoma: a nationwide survey

Therapeutic strategy for multiple myeloma -recent progress

Final results of a phase I study of carfilzomib, lenalidomide, and dexamethasone for heavily pretreated multiple myeloma

Future projection of cancer patients with cardiovascular disease in Japan by the year 2039: a pilot study

RETRACTED ARTICLE: High-dose therapy and autologous stem cell transplantation for relapsed or high-risk diffuse large B-cell lymphoma: a nationwide survey

Management of multiple myeloma in Asia: resource-stratified guidelines

Pomalidomide alone or in combination with dexamethasone in Japanese patients with refractory or relapsed and refractory multiple myeloma

Survival of Multiple Myeloma Patients Aged 65-70 Years in the Era of Novel Agents and Autologous Stem Cell Transplantation

Pretreatment evaluation of fluorescence resonance energy transfer‐based drug sensitivity test for patients with chronic myelogenous leukemia treated with dasatinib

Elotuzumab with lenalidomide and dexamethasone for Japanese patients with relapsed/refractory multiple myeloma: phase 1 study

Risk factors and timing of autologous stem cell transplantation for patients with peripheral T-cell lymphoma

Suchergebnisse filtern